Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of a standard opioid (such as morphine, oxycodone, hydrocodone, or codeine) and methocarbamol. Opioids are potent analgesics that act primarily as agonists at the mu-opioid receptor to provide pain relief by inhibiting ascending pain pathways in the central nervous system. Methocarbamol is a centrally acting skeletal muscle relaxant with an unclear mechanism of action; it is thought to depress polysynaptic reflexes in the spinal cord and decrease nerve transmission in spinal and supraspinal pathways. The combination may be used for acute musculoskeletal pain where both significant analgesia and muscle relaxation are desired. However, combining opioids with methocarbamol increases the risk of central nervous system depression, including drowsiness, respiratory depression, confusion, hypotension, seizures, coma, or death[1][5][6]. This combination should be used cautiously due to additive sedative effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standard opioid + methocarbamol.